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Objective: To evaluate the effectiveness and long-term outcome of Gamma Knife radiosurgery (GKRS) for
tiny vestibular schwannomas (VSs) detected by three-dimensional fast imaging employing steady-state
acquisition magnetic resonance (3D-FIESTA MR).
Materials and methods: Between January and December 2004, 3D-FIESTA MR of the brain was performed
in patients who had physical health examinations at the Buddhist Tzu Chi General Hospital (Hualien,
Taiwan). Tiny intracanalicular VSs (deﬁned as a tumor volume < 0.5 cm2) was detected in 13 patients
(8 women and 5 men). The mean age of the patients was 60 years (range, 45e84 years). Hearing function
was graded using the GardnereRobertson (GR) classiﬁcation. Dose planning was performed on intra-
operative stereotactic contrast-enhanced images using multiple 4-mm isocenters. The mean tumor
volume was 0.098 cm2 (range, 0.013e0.4 cm2). The mean margin dose was 12.4 Gy (range, 11e14 Gy),
and the isodose line was set at a mean of 53.8% (range, 50e70%).
Results: Twelve patients had GR Grade I or II hearing before GKRS, and GR I or II hearing was maintained
in 11 patients. Facial and trigeminal nerve functions were preserved in all patients. The tumor control rate
was 100% at a mean follow-up period of 9.8 ± 1.1 years (range, 76e126 months). One patient developed
acute vertigo 1 day after GKRS, which subsided after short-term use of steroids and did not recur.
Conclusion: With theapplicationof 3D-FIESTA, tinyVSs canbedetectedearly. Because low-dose (12e14Gy)
GKRS is safe and effective for long-termcontrol of the growthof tumorswith acceptable preservation rate of
hearing function, it may be worthwhile to use 3D-FIESTA to detect tiny VSs and treat the patients using
GKRS.
Copyright © 2014, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Vestibular schwannomas (VSs) represent approximately 10% of
all primary brain tumors, with an estimated annual incidence ofsurgery, Buddhist Tzu Chi
Road, Hualien, Taiwan.
).
elief Tzu Chi Foundation. Publisheone case per 100,000 individuals [1,2]. A European report showed
that the number of VSs diagnosed each year has increased threefold
in recent decades from the era of radiography to the era of
computed tomography and magnetic resonance imaging (MRI).
Over the same period, the mean size of the tumor at the time of
diagnosis has gradually decreased from 35 (extrameatal diameter)
to 10 mm [3e5]. Similar changes in the incidence and size have
been reported in other studies [4e6]. With the decrease in tumor
size at diagnosis, there are fewer symptoms, and unilateral senso-
rineural hearing reduction may be the only symptom [6e8].d by Elsevier Taiwan LLC. All rights reserved.
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dimensional fast imaging employing steady-state acquisition
magnetic resonance (3D-FIESTA MR), the chances of ﬁnding
asymptomatic patients with tiny VSs have improved. Using the 3D-
FIESTA technique, the anatomic structures within the internal
acoustic canal (IAC) can be clearly visualized without gadolinium
enhancement [9]. Therefore, there has been an increase in inci-
dental visualization of intracanalicular VSs without signiﬁcant
symptoms and signs (Fig. 1). This raises a question about whether
these tumors in the acoustic canal should be treated.
Gamma Knife radiosurgery (GKRS) was ﬁrst performed by Lek-
sell in 1969 [10]. Over the years, with advanced dose-planning
software, MRI-guided dose planning, and dose optimization, the
evolution of radiosurgery has revolutionized the management of
VSs [11]. During the last decade, radiosurgery has emerged as an
effective alternative to surgical removal of small- and moderate-
sized VSs. To date, the concepts of performing radiosurgery for
VSs have focused on the control of tumor growth, preservation of
hearing function, and prevention of other cranial neuropathy with
the application of low-dose radiosurgery [12e21].
This article seeks to delineate the long-term outcome of GKRS
for proactive treatment of tiny intracanalicular VSs detected by 3D-
FIESTA MR.
2. Materials and methods
2.1. 3D-FIESTA MR study
Between January and December 2004, 3D-FIESTA MR studies
were performed on patients who received physical health ex-
aminations. The 3D-FIESTA pulse sequence provides excellent
high-resolution images of ﬂuid-ﬁlled structures with very short
acquisition times. The FIESTA technique employs ultrashort
repetition times and echo times, with very fast scan times and
outstanding image contrast. This bright ﬂuid sequence uses
steady-state contrast mechanisms to provide high signal-to-noise
ratio images with a strong signal from ﬂuid while effectively
suppressing background tissue. With the application of 3D-
FIESTA MR, those anatomic structures within the acoustic canal
can be better delineated, and contrast medium is not needed atFig. 1. (A) Three-dimensional fast imaging employing steady-state acquisition magnetic reso
internal acoustic canal. (B) Contrast magnetic resonance-enhanced study conﬁrms the tinythe primary survey. Because gadolinium-enhanced MRI remains
the gold standard for the detection of VSs, contrast study could be
reserved for those patients with tumors shown on 3D-FIESTA MR
(Fig. 2).
Unilateral tiny VSs (deﬁned as a tumor volume < 0.5 cm2) were
detected in 13 patients with this procedure. The clinical charac-
teristics of these patients are listed in Table 1. The patient series
consisted of eight women and ﬁve men. The median age of patients
was 60 years (range, 45e84 years). Audiograms for hearing func-
tion tests on the lesion side were evaluated according to the
GardnereRobertson (GR) classiﬁcation [22]. Twelve patients had
serviceable hearing function on the lesion side ear before treatment
(deﬁned as GR Class I and II), and one patient had Class III hearing
function. Eight patients experienced minor symptoms such as
tinnitus, vertigo, headache, or a combination of these symptoms.
One patient had a family history of neuroﬁbromatosis (type II), and
his unilateral VS was found in a family survey by 3D-FIESTA study.
Neither trigeminal nor facial neuropathy could be detected before
treatment in any of the 13 patients. The tumor volume varied from
0.013 to 0.4 cm2.
2.2. Radiosurgery technique
The procedure began with rigid ﬁxation of a Leksell stereotactic
frame (Model C; Elekta Instruments, Stockholm, Sweden) to
the patient's head. Local anesthesia was applied to the scalp
(5% bupivacaine and 2% lidocaine). MR stereotactic images were
acquired with a ﬁducial system attached to the stereotactic frame
and transported through a ﬁber optic Ethernet cable to the Gam-
maPlan (Elekta Instruments) computer, in which images were
checked for distortion/accuracy. Planning was performed on 1- or
2-mm slice thickness axial MR images with coronal and sagittal
reconstructions. After optimizing the plan, a maximum dose to the
target was determined. Radiosurgery was performed with a 201-
source, cobalt-60 Gamma Knife and the patients' heads and ste-
reotactic frames were immobilized within the appropriate colli-
mator helmet at a calculated target coordinate. The treatment was
accomplished in a single session by positioning the head serially for
each subsequent isocenter until a fully conformal ﬁeld encom-
passed the tumor volume.nance shows an intracanalicular vestibular schwannoma (VS, white arrow) in the right
VS (white arrow).
Fig. 2. Serial magnetic resonance imaging (MRI) of a 55-year-old man with a tiny vestibular schwannoma (VS). (A) Axial MRI at the time of Gamma Knife radiosurgery (GKRS)
demonstrating a tiny VS in the right internal acoustic canal. (B) Follow-up MRI shows central hypointensity in the tiny VS (circle) 6 months after GKRS. (C) Follow-up MRI 3 years
and 4 months after GKRS shows normalization of the tiny VS without enlargement, and the central hypointensity has disappeared. The comparable pure tone audiogram checked
around the time of the aforementioned MRI studies showed no signiﬁcant changes in 500e4k but a decline in some high-pitched sounds. Images (D), (E), and (F) correspond with
images (A), (B), and (C), respectively.
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Three-dimensional volume-acquisition MRI was performed us-
ing a spoiled gradient recalled acquisition in steady-state pulse
sequence (divided into 40e60 slices,1- or 2-mm thickness) to cover
the entire lesion surrounding the critical structures.2.4. Radiosurgical dose planning
A conformal plan was created using GammaPlan Software
(Elekta Instruments). Because the tumors were small, the smallest
beam diameters were used. Only 4-mm collimators were used to
irradiate the intracanalicular tiny VSs in this study. As the facial and
the acoustic nerve complex usually coursed along the anterior
margin of the tumor, the dose plan was highly conformal in this
area. The tumor margin doses were 11 (n¼ 1), 12 (n¼ 7), 13 (n¼ 4),
and 14 Gy (n ¼ 1) and the median margin dose was 12 Gy. The
maximum dose ranged from 16 to 26 Gy (median, 24 Gy). The
marginal tumor dosewas prescribed to the 50% isodose line in eight
patients, 55% in three, 60% in one, and 75% in one. The number of
isocenters used for each patient varied from one to 10 (median, 4).Table 1
Clinical characteristics of 13 tiny vestibular schwannoma patients.
Characteristics Values
No. of patients 13
Age (y) 60.9 ± 10.0 (45e84)
Sex (M:F) 5:8
Tumor volume (cm3) 0.098 ± 0.118 (0.013e0.400)
Minor symptomsa 12
Pre-GK hearing status
GR Grade I 10
GR Grade II 2
GR Grade III 1
Prescription dose (Gy) 12.4 ± 0.8 (11e14)
Isodose line percentage 53.8 ± 7.1 (50e75)
No. of shots 4.4 ± 2.7 (1e10)
Treatment with plug shielding 4
Follow-up period (mo) 118 ± 13 (76e126)
F¼ female; GR¼ GardnereRobertson grade; M¼male; pre-GK¼ pre-Gamma Knife
radiosurgery.
a Minor symptoms include balance problems, tinnitus, vertigo, dizziness, or
headache.In four patients, the plugging method was adopted for shaping the
isodose line to achieve higher conformality.
2.5. Postoperative care and evaluation
All patients received an intravenous dose of betamethasone
(8 mg) at the end of the procedure. The stereotactic frame was
removed immediately after radiosurgery. The patients were
observed in the ward and were discharged 1 day after treatment.
After radiosurgery, all patients were followed with serial
gadolinium-enhanced MRI, at around 6 and 18 months post-GKRS,
and then every year subsequently. All patients who had preserved
hearing were advised to undergo audiologic evaluation such as a
pure tone audiogram and speech discrimination study during an
MR follow up. Audiological data were compared with our pre-
treatment baseline data. Preradiosurgery and postradiosurgery
hearing were graded using the modiﬁed GR classiﬁcation [22]. In
addition, preradiosurgery and postradiosurgery facial and trigem-
inal nerve functions were also assessed in all patients, and the facial
nerve functions were classiﬁed according to the HouseeBrackmann
grading system [23]. The duration of follow up in this series varied
from 76 to 126 months (median, 118 months).
3. Results
3.1. Tumor growth control
Radiographic tumor progression was strictly deﬁned as any
temporary or sustained increase in the tumor diameter by at least
1 mm in two dimensions or 2 mm in any direction. The median
follow-up period was 118 months (range, 76e126 months). Loss of
central contrast uptake with minimal temporary tumor enlarge-
ment was noted in four patients, but these tumors were the same
size as or smaller than the original tumors 1 or 2 years later. There
was neither any change nor decrease in the tumor size on long-
term follow up after GKRS. The clinical and radiological tumor
control rate was 100%.
3.2. Hearing preservation
Audiological data are presented in Table 2. Immediately after
radiosurgery, all patients (100%) maintained their preoperative
Table 2









I 0e30 70e100 10 9
II 31e50 50e69 2 2
III 51e90 5e49 1 2
IV 91 to maximum 1e4 0 0
V None detectable 0 0 0
GK ¼ Gamma Knife radiosurgery.
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were maintained and preserved in 11 of 12 patients with Grade I to
II hearing levels.
3.3. Facial and trigeminal nerve functions
All 13 patients who had Grade I facial function before the sur-
gery preserved their function after radiosurgery. No patient
developed trigeminal neuropathy.
3.4. Functional outcome
All patients were discharged 1 day after radiosurgery and
returned to their normal activities. No patient had a change in
employment status because of this disease and treatment during
the follow up; in addition, none of the patients in this series
required additional surgery for the tumor by the time of the last
follow up. Only one patient had adverse radiation effects with acute
exacerbation of dizziness and vertigo for 5 days after radiosurgery.
However, these symptoms improved after treatment with steroids
and did not recur during the follow-up period.
4. Discussion
4.1. Treatment modality
The treatment options offered to patients with VSs have
changed. About three decades ago, treatment was limited to
microsurgery. Microsurgery was considered the standard approach
for treatment of VSs, especially for large tumors compressing the
brain stem in patients with balance disability. With small tumors or
intracanalicular VSs, the options included a wait-and-see policy,
microsurgery, and stereotactic radiosurgery. In microsurgery, con-
cerns stem from the potential morbidities associated with intra-
cranial procedures. Both tumor size and the surgeon's experience
are risk factors [24]. Hearing loss is an obvious morbidity, and
deafness reportedly occurs in 50% of patients [25]. Preservation of
hearing has been reported at very low rates in patients with tumors
greater than 2 cm [24]. A meta-analysis of the literature from the
1990s identiﬁed other complications in 21.9% of cases [26]. The
mortality rate was very low (0.3%) and cerebrospinal ﬂuid (CSF)
leak was the most common morbidity (10.95%). Other complica-
tions were facial nerve transection (3.9%), meningitis (1.2%), and
damage to other cranial nerves (1.1%). Another review of the liter-
ature reported mortality in 0e2% of patients, CSF leakage in 3e15%,
facial nerve transection in 2.5e7%, and meningitis in 1e3% [24].
Data on minor symptoms such as tinnitus, vertigo, and balance
have rarely been reported. Regis et al [20] used objective results
and questionnaires to compare the results of radiosurgery with
microsurgery. The results indicated no new facial weakness in 100%
of patients who underwent GKRS compared with 63% of patients
who underwent microsurgery. Ninety-one percent of patients
treated with GKRS (61% for microsurgery) had no functionaldeterioration after treatment. The mean hospital stay was 3 days
after GKRS and 23 days after microsurgery. All working patients
who underwent GKRS continued the same professional activities,
compared with 56% in the microsurgery arm. The mean time away
fromwork was 7 days for the GKRS group compared with 130 days
for patients in the microsurgery group. Seventy percent of patients
with a Class I preoperative hearing level (GR scale) had preserved
functional hearing after GKRS (Class I and Class II) compared with
only 37.5% in the microsurgery group. Findings after 4 years' follow
up indicated that GKRS provided better functional outcomes than
microsurgery. In our series, only one patient developed reduction of
the hearing from Grade II to III; all other patients with Grade I
hearing showed good preservation of hearing function. Patients
with IAC tumors usually have no signiﬁcant clinical symptoms and
signs. These patients might desire a less invasive intervention than
microsurgery, such as await-and-see policy or GKRS, which usually
does not require general anesthesia or opening of the skull.
4.2. Radiosurgical tumor control and dosage
The ultimate goal of radiosurgery in VSs is control of tumor
growth. Recent reports suggest an encouraging tumor control rate
of 93e100% after performing radiosurgery for VSs [15,17,21,27,28].
Kondziolka et al [15] studied the 5e10-year outcomes in 162 pa-
tients with acoustic tumors who underwent radiosurgery at the
University of Pittsburgh. In that study, a long-term tumor control
rate of 98% was reported; 62% of tumors became smaller, 33%
remained unchanged, and 6% became slightly larger. Some tumors
initially enlarged 1e2 mm during the ﬁrst 6e12 months after
radiosurgery as they lost their central contrast enhancement. In our
study, four patients had a similar response after radiosurgery. These
tumors invariably regressed in volume compared with their pre-
radiosurgical size. Only 2% of patients in that study underwent
tumor resection after radiosurgery. Niranjan et al [17] analyzed the
outcome of intracanalicular acoustic tumor radiosurgery per-
formed at the University of Pittsburgh. All patients (100%) had
imaging-documented tumor growth control. Flickinger et al [28]
performed an outcome analysis of VSs patients treated between
August 1992 and August 1997 at the University of Pittsburgh.
Radiosurgery was performed as the primary treatment in 192 pa-
tients. The actual 5-year clinical tumor control rate (no requirement
for surgical intervention) was 99.4% ± 0.6%.
The dose prescription for VSs has also changed signiﬁcantly over
the last 15 years. Initially, the dose delivered to the tumor margin
(i.e., 18e20 Gy) was based on experience in a Swedish study [29].
However, the dose to the tumor margin was decreased to an
average of 16e18 Gy within the ﬁrst 2 years and by 1992, it was
decreased further to 14e16 Gy [15]. Gradual reduction in doses has
improved hearing preservation rates and reduced facial and tri-
geminal neuropathies. For the last 10 years, 13 Gy has been selected
as the usual tumor margin dose [12]. This dose has been associated
with a low complication rate while maintaining a high rate of tu-
mor control.
The goals of VSs radiosurgery have evolved and there is much
more emphasis on the maintenance of neurological functions and
prevention of new neurological deﬁcits along with long-term pre-
vention of tumor growth. In 1996, Flickinger et al [30] deﬁned the
relationships between dose and tumor diameter for the risks of
developing trigeminal, facial, and acoustic neuropathies after per-
forming radiosurgery for VSs. The development of postradiosurgery
neuropathies affecting cranial nerves V, VII, and VIII was correlated
with a minimum tumor dose and transverse tumor diameter [30].
This result might suggest that there would be lower complication
rates after radiosurgery if those VSs are treated as early as possible.
In our series, we used the 3D-FIESTA to detect IAC VSs, and
C.-F. Su et al. / Tzu Chi Medical Journal 26 (2014) 132e137136proactively treated patients with a low dosage. In the 10-year
follow up, a tumor control rate of 100% and a low rate of hearing
reduction were noted. We preserved serviceable GR hearing levels
in 11 of the 12 patients treated in this study. This ﬁnding seems
compatible with the results reported by Flickinger and co-workers.
4.3. Wait-and-see policy
For patients with small or medium intracanalicular VSs, one of
the alternatives is a wait-and-see policy. Most patients with small
tumors do not have a rapidly progressive neurological syndrome
yet some have persistent hearing loss, tinnitus, vertigo, headache,
or a combination of these symptoms. These symptoms do not
improve consistently after resection or radiosurgery [31]. There-
fore, many patients now prefer a policy with minimal risk.
One pathological study postulated that IAC tumorsmight belong
to a distinct category of VSs. Martin et al [32] reported on 144 VSs
and showed that 100% of IAC VSs displayed Antoni type A archi-
tecture, whereas the large tumors had a B-type pattern (76.8%). This
might indicate that IAC VSs are less aggressive and most are stable
in the long term. Therefore, many researchers recommend
sequential follow up for small IAC tumors with increased attention
to changes in tumor volume and hearing function. However, un-
treated tumors in the brain did grow in a proportion of patients.
Suryanarayanan et al [33] assessed the outcome of conservative
management in 436 patients with VSs in an observational study.
One third of tumors did grow during a mean follow up of 3.6 years.
The authors, however, did not recommend conservative manage-
ment for sporadic tumors with an intracranial diameter of 1.5 cm or
more. In growing tumors, the mean growth rate was 1.1 mm/year
for sporadic tumors and 1.7 mm/year for neuroﬁbromatosis type II
tumors. Similar results were reported with a wait-and-see policy in
other reviews of VSs behavior [25,33e36]. In our study, the tumors
did not grow during long-term follow up after low-dose GKRS,
although transient tumor enlargement with central hypointensity
was found in four cases. However, can a wait-and-see policy be
more beneﬁcial for patients with IAC VSs? Can a small tumor grow
and functional hearing change during observation or remain un-
changed for the patient's entire life span? Regis et al [37] compared
a wait-and-see policy and proactive GKRS in small IAC VSs. Forty-
seven patients with intracanalicular VSs were followed prospec-
tively along with a control group of 34 patients with unilateral
intracanalicular VSs who were consecutively treated by GKRS and
had functional hearing at the time of radiosurgery. Treatment
failure was deﬁned as tumor growth requiring treatment. In the
wait-and-see group, treatment failure was observed in 35 patients
(74%) but in the control (GKRS) group, it occurred in only one (3%)
of the 34 patients. In the wait-and-see group, 60% of patients
demonstrated no change of GR hearing class. Fifteen patients (38%)
experienced more than 10 dB of hearing loss and two of them
became deaf. At 3, 4, and 5 years, the useful hearing preservation
rates were 75%, 52%, and 41% in the wait-and-see group, but 77%,
70%, and 64% in the GKRS control group, respectively. Thus, the
chances of maintaining functional hearing and avoiding further
intervention were much higher in cases treated by GKRS (79% and
60% at 2 and 5 years, respectively) than in cases managed by the
wait-and-see strategy (43% and 14% at 2 and 5 years, respectively).
There is still no consensus regarding the selection of candidates
for therapeutic intervention because the growth rate of VSs is un-
predictable [38]. However, a management strategy that maintains
cranial nerve functions, reduces treatment-associated morbidity,
and allows the patient to resume a normal lifestyle as quickly as
possible after intervention is desirable [31]. Many patients, espe-
cially those with minor symptoms and tiny VSs, which are detected
early, might prefer radiosurgery to surgical resection because of thelower morbidity and similar rates of long-term tumor control with
this procedure. Our series showed good preservation of cranial
nerve functions as well as the good control of tumor growth over 10
years. We posit that the proactive treatment of tiny IAC VSs is
desirable.
In conclusion, with the application of 3D-FIESTA, tiny VSs can be
detected early. The low irradiation dose (12e14 Gy) for GKRS has
been proven effective for long-term control of tumors with good
preservation of neurological functions. It may be worthwhile to use
3D-FIESTA to detect tiny VSs and treat those tumors with low-dose
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